Trial · NCT07259317
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07259317, Phase 2, Recruiting, Corcept Therapeutics
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma. Trials, record NCT07259317. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07259317
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
- NCT number
- NCT07259317
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 80 participants, estimated
- Lead sponsor
- Corcept Therapeutics
- Conditions
- Adenocarcinoma, Carcinoma, Pancreatic Ductal
- Interventions
- Relacorilant, Nab-paclitaxel, Gemcitabine
- First posted
- 2025-12-02
- Last updated
- 2026-09-25
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent of Patients who Experience Dose Limiting Toxicity (DLT) (Part 1) | Up to 28 days after the first dose of study treatment | The percentage of patients with a DLT is used to estimate maximum tolerated dose (MTD), the most intense dose/schedule among those evaluated at which \<33% of patients experience DLT. |
| Primary | Number of Patients with 1 or More Adverse Events (AEs) Leading to Study Drug Discontinuations or Dose Modifications (Part 1) | Time of first dose up to 30 days after last dose | |
| Primary | Progression-Free Survival (PFS) (Part 2) | From date of enrollment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months | To evaluate PFS as the time from enrollment until first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by the Investigator, or death due to any cause, whichever comes first. |
| Secondary | Maximum Plasma Concentration (Cmax) of Relacorilant (Part 1 and Part 2) | Pre- and postdose on Cycle 1 Day 15 (each cycle is 28 days) | |
| Secondary | Area Under the Plasma Concentration-time Curve (AUC) of Relacorilant (Part 1 and Part 2) | Pre- and postdose on Cycle 1 Day 15 (each cycle is 28 days) | |
| Secondary | Cmax of Nab-paclitaxel (Part 1 and Part 2) | At serial timepoints postdose on Cycle 1 Day 15 (each cycle is 28 days) | |
| Secondary | AUC of Nab-paclitaxel (Part 1 and Part 2) | At serial timepoints postdose on Cycle 1 Day 15 (each cycle is 28 days) | |
| Secondary | Overall Survival (OS) (Part 2) | From date of enrollment until the date of death from any cause, whichever comes first, assessed up to 19 months | |
| Secondary | Best Overall Response (BOR) (Part 2) | From date of enrollment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months | |
| Secondary | Objective Response Rate (ORR) (Part 2) | From date of enrollment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months | To evaluate the proportion of patients with measurable disease at Baseline who attain complete response (CR) or partial response (PR) by RECIST version 1.1. |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07259317
GET https://conductscience.org/api/trials/v1/NCT07259317/registered